Bipolar disorder nursing: assessment, interventions, and pharmacology

Bipolar disorder affects approximately 4% of the population worldwide and carries a 20–30 times higher suicide risk compared to the general population — one of the highest of any psychiatric diagnosis. It is defined by recurrent episodes of mania or hypomania interspersed with periods of depression. The illness is chronic, episodic, and highly treatable when nurses and patients understand the pharmacology, early warning signs, and relapse prevention strategies.

Fast-scan: bipolar disorder types and pharmacology snapshot

Quick pharmacology snapshot

This reference covers DSM-5 criteria, phase-specific nursing interventions, complete mood stabilizer pharmacology, lithium toxicity management, therapeutic communication, and discharge planning. Use it alongside the depression nursing reference, schizophrenia nursing reference, pharmacology nursing guide, and drug classifications reference for integrated psychiatric coverage.

DSM-5 diagnostic criteria

Bipolar I disorder

The defining feature is at least one manic episode. Depressive episodes are common but not required for diagnosis.

Manic episode criteria (all four required):

A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood AND abnormally and persistently increased goal-directed activity or energy, lasting at least 1 week and present most of the day, nearly every day (or any duration if hospitalization is necessary).

B. During the period of mood disturbance and increased energy, three or more of the following symptoms are present to a significant degree (four if the mood is only irritable):

• Inflated self-esteem or grandiosity
• Decreased need for sleep (feels rested after only 3 hours)
• More talkative than usual, or pressure to keep talking
• Flight of ideas or subjective experience of racing thoughts
• Distractibility (attention easily drawn to irrelevant stimuli)
• Increase in goal-directed activity or psychomotor agitation
• Excessive involvement in activities with high potential for painful consequences (spending sprees, sexual indiscretions, foolish investments)

C. The mood disturbance is severe enough to cause marked impairment in social or occupational functioning, or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features.

D. The episode is not attributable to physiological effects of a substance or another medical condition.

Bipolar II disorder

Requires at least one hypomanic episode and at least one major depressive episode. A full manic episode has never occurred.

Hypomanic episode: Same symptom criteria as mania (Criterion B above), but the episode lasts at least 4 consecutive days. The episode is not severe enough to cause marked functional impairment, does not require hospitalization, and has no psychotic features.

Key distinction from Bipolar I: The hypomanic episode causes an unequivocal change in functioning that is observable by others — but it is not severe enough to markedly impair function.

Major depressive episode (in bipolar context): Five or more of the following, present most of the day, nearly every day for at least 2 weeks: depressed mood, loss of interest or pleasure (anhedonia), weight/appetite change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, diminished concentration, recurrent thoughts of death or suicidal ideation.

Cyclothymic disorder

A 2-year history (1 year in children and adolescents) of numerous periods with hypomanic symptoms that do not meet criteria for a hypomanic episode AND numerous periods with depressive symptoms that do not meet criteria for a major depressive episode. During the 2-year period, the hypomanic and depressive periods have been present for at least half the time and the individual has not been without symptoms for more than 2 months at a time.

DSM-5 specifiers

Phases and symptom profiles

DIGFAST mnemonic for mania

The DIGFAST mnemonic captures the seven core features of a manic episode:

• D — Distractibility
• I — Irresponsibility / impulsivity / risky behavior
• G — Grandiosity
• F — Flight of ideas
• A — Activity increase (goal-directed) / psychomotor Agitation
• S — Sleep decreased (need, not just duration)
• T — Talkativeness / pressured speech

Detailed symptom comparison by phase

Nursing assessment

Mental status exam (MSE) by phase

The MSE provides a systematic snapshot of current psychiatric functioning. Document each component formally on admission and with significant changes.

Safety assessment

Bipolar disorder carries a lifetime suicide mortality rate of approximately 15–20% in untreated populations, and individuals with bipolar disorder are 20–30 times more likely to die by suicide than the general population. Mixed episodes carry the highest acute risk — combining the hopelessness of depression with the impulsivity and energy of mania.

Conduct a structured safety assessment at every encounter using the Columbia Suicide Severity Rating Scale (C-SSRS):

• Ideation: Passive wish to be dead vs. active suicidal ideation with or without intent or plan
• Plan: Specificity, lethality, and access to means
• Intent: Degree of intent to act
• Behavior: Past attempts, aborted attempts, preparatory behaviors
• Self-harm: Non-suicidal self-injury (NSSI) — separate from suicidality but requires assessment

Risk factors to document specifically in bipolar disorder:

• Mixed features or rapid cycling (highest acute risk)
• Recent manic or psychotic episode
• Substance use comorbidity (significantly amplifies risk)
• History of prior attempts (strongest single predictor)
• Social isolation or recent loss
• Non-adherence to medications
• Access to firearms or lethal means

Young Mania Rating Scale (YMRS)

The YMRS is an 11-item clinician-administered scale assessing mania severity over the preceding 48 hours. Items include elevated mood, motor activity/energy, sexual interest, sleep, irritability, speech rate and amount, language/thought disorder, thought content, disruptive/aggressive behavior, appearance, and insight.

• Scoring: 0–60 total; higher scores indicate greater severity
• Interpretation: 0–12 = minimal/none; 13–19 = mild; 20–25 = moderate; 26–37 = marked; 38+ = severe
• Use: Admission baseline, treatment response monitoring, discharge documentation
• Nursing role: Administer and document; report scores ≥20 as requiring provider notification of inadequate treatment response

Substance use screening

Substance use disorders co-occur in approximately 50% of individuals with bipolar I disorder — the highest comorbidity rate of any major psychiatric diagnosis. Alcohol is the most common substance. Screen using AUDIT-C or CAGE at every encounter. Substance use destabilizes mood, impairs medication adherence, and dramatically increases suicide risk.

Sleep assessment

Sleep disturbance is frequently the earliest indicator of an emerging manic episode — often preceding other symptoms by days. A patient who reports “I only slept 3 hours but I feel great” warrants immediate clinical review. Document:

• Hours of sleep per night (subjective vs. objective via observation if inpatient)
• Whether decreased sleep correlates with decreased need (mania) or inability to sleep (anxiety/depression)
• Changes in sleep pattern from baseline

Nursing interventions by phase

Manic phase interventions

Depressive phase interventions

Mixed features and rapid cycling — heightened vigilance protocol

Mixed features are the highest-risk phase of bipolar disorder. The patient experiences depressive hopelessness combined with manic energy and impulsivity — a combination that sharply elevates suicide risk and lethality of any attempt.

Nursing priorities:

• Increase observation frequency to 1:1 or q15-minute checks minimum
• Conduct Columbia C-SSRS assessment at minimum every shift
• Ensure means restriction is thorough — patients will use impulsive energy to locate overlooked items
• Avoid antidepressants (provider decision, but nursing should be aware and question any such order)
• Document all behavioral changes hourly — switches in polarity can occur rapidly

Mood stabilizers — primary agents

Lithium

Lithium remains the gold standard mood stabilizer for bipolar I disorder and is the only pharmacological agent with demonstrated antisuicidal effects in bipolar disorder — an important patient education point.

Mechanism: Lithium modulates multiple intracellular signaling pathways, inhibits inositol monophosphatase (depleting second messenger systems that drive manic symptoms), and influences sodium transport across neuronal cell membranes. It also has neuroprotective properties at therapeutic concentrations.

Dosing: Titrated to therapeutic serum levels. Check levels 5–7 days after any dose change and 12 hours after the last dose.

• Acute mania: target 0.8–1.2 mEq/L
• Maintenance: target 0.6–1.0 mEq/L (lower end reduces renal and thyroid burden over time)

Monitoring schedule:

Patient teaching — lithium:

• Take with food to reduce GI upset
• Maintain consistent sodium intake — low-sodium diet causes lithium retention and toxicity; high-sodium loss (sweating, diarrhea, vomiting) does the same
• Drink 2–3 liters of fluid daily under normal conditions; increase during exercise or hot weather
• Avoid NSAIDs (ibuprofen, naproxen) — they reduce renal clearance of lithium and can cause toxicity; use acetaminophen instead
• Report early toxicity signs immediately: diarrhea, vomiting, coarse tremor, drowsiness, confusion
• Do not skip doses; do not double-dose if a dose is missed
• Carry lithium ID card; inform all providers including dentists

Lithium toxicity — detailed reference

Risk factors for toxicity:

• Dehydration (any cause: vomiting, diarrhea, fever, excessive sweating, inadequate intake)
• Low-sodium diet or sodium-wasting conditions
• NSAID use (ibuprofen, naproxen, indomethacin)
• Thiazide and loop diuretics (reduce renal lithium clearance)
• ACE inhibitors and ARBs (reduce renal lithium clearance)
• Renal impairment (acute or chronic)
• Overdose (intentional or accidental)

LMNOP mnemonic for toxicity signs:

• L — Lethargy
• M — Movement problems (coarse tremor, ataxia, coordination loss)
• N — Nausea/vomiting
• O — Obtundation (impaired consciousness)
• P — Polyuria/polydipsia

Three-stage toxicity table:

Hemodialysis threshold: Levels >3.0 mEq/L, seizures, severe renal impairment, or hemodynamic instability — regardless of level. Hemodialysis is the only effective method to rapidly reduce lithium levels.

Lab values context: See the nursing lab values cheat sheet and electrolyte imbalances reference for sodium-lithium interaction context and normal reference ranges.

Valproate (divalproex sodium / Depakote)

Mechanism: Enhances GABA activity and reduces glutamate activity; stabilizes neuronal membranes. Effective for acute mania, mixed features, and rapid cycling.

Therapeutic range: 50–125 mcg/mL for bipolar disorder (some sources extend to 50–150 mcg/mL for acute mania)

Monitoring:

Critical nursing consideration — teratogenicity: Valproate is associated with neural tube defects (spina bifida, approximately 1–2% risk), cardiac malformations, and cognitive impairment in exposed children. It is classified as FDA Pregnancy Category X (do not use in pregnancy) and requires REMS enrollment (Valproate Risk Evaluation and Mitigation Strategy) for women of childbearing potential. Assess pregnancy status before initiation. Ensure contraception counseling is documented.

Patient teaching: Report bruising, bleeding, jaundice, or abdominal pain. Take with food. Do not crush extended-release tablets.

Lamotrigine (Lamictal)

Mechanism: Inhibits voltage-gated sodium channels, reducing glutamate release. Unlike lithium and valproate, lamotrigine is more effective for bipolar depression maintenance than for acute mania. It does not have a controlled study-supported acute antimanic effect.

Indication in bipolar: Bipolar depression maintenance; Bipolar II maintenance. It is not effective for acute mania.

Critical nursing consideration — Stevens-Johnson Syndrome (SJS): Rapid titration of lamotrigine dramatically increases the risk of SJS, a severe and potentially fatal mucocutaneous reaction. The titration schedule is slow by design — typically starting at 25 mg/day and increasing no faster than every 2 weeks.

• Any new rash while on lamotrigine must be considered SJS until proven otherwise
• Hold the drug and notify the provider immediately upon any rash — do not wait to see if it resolves
• Distinguish benign maculopapular rash (relatively common) from SJS (mucosal involvement, blistering, systemic symptoms) — provider makes this determination, but nurses must escalate any rash without delay

Titration schedule: The prescribing schedule is extended because valproate doubles lamotrigine levels (inhibits glucuronidation), while carbamazepine and other enzyme inducers halve them. Dose adjustments are required with concurrent mood stabilizers.

Carbamazepine (Tegretol)

Mechanism: Sodium channel blockade, reducing neuronal firing rate. FDA-approved for acute mania; also used in maintenance.

Autoinduction: Carbamazepine induces its own hepatic metabolism (CYP3A4) — levels drop significantly over the first 4–6 weeks as induction occurs. Dose adjustments are required during this period.

Monitoring:

• CBC with differential (baseline and every 2 weeks × 2 months, then every 3 months) — agranulocytosis and aplastic anemia risk (rare but potentially fatal)
• LFTs (baseline; periodic)
• Serum carbamazepine level (therapeutic range: 4–12 mcg/mL)
• Sodium — carbamazepine causes SIADH and hyponatremia; monitor electrolytes

Drug interactions: Strong CYP3A4 inducer — reduces levels of oral contraceptives, warfarin, many antipsychotics, and other medications. Thorough medication reconciliation is required.

Atypical antipsychotics in bipolar disorder

Metabolic monitoring for all atypical antipsychotics:

All atypical antipsychotics carry an FDA class warning for metabolic effects. Per ADA/APA consensus guidelines, monitor:

• Weight and BMI: baseline, 4 weeks, 8 weeks, 12 weeks, then quarterly
• Fasting glucose: baseline, 12 weeks, then annually
• Fasting lipid panel: baseline, 12 weeks, then every 5 years (annually if abnormal)
• Blood pressure: baseline, 12 weeks, annually
• Waist circumference: baseline, annually

See the pharmacology nursing guide for detailed antipsychotic monitoring protocol and EPS management.

Therapeutic communication in bipolar disorder

Effective communication adjusts to the patient’s phase. Using the same approach across phases reduces therapeutic effectiveness and can escalate conflict.

Patient and family education

Non-adherence to medication is the single most common cause of relapse in bipolar disorder. Education must be ongoing, phase-appropriate (acute mania is not the time for complex teaching), and include the family or support system whenever the patient consents.

Core medication education

• Why mood stabilizers are necessary: Bipolar disorder involves a biological vulnerability to mood cycling. Medications reduce the frequency, duration, and severity of episodes — but they do not cure the underlying condition. Stopping medications abruptly is the fastest route to relapse.
• Why patients stop medications: Common reasons include feeling well (paradox — the medication is working), intolerable side effects (address proactively), weight gain (common; address with lifestyle support and medication adjustment if needed), desire to feel the “highs” again (common in mania — address with motivational interviewing), stigma.
• Adherence strategies: Pill organizers, phone alarms, pharmacy blister packs, medication apps, involving a support person in medication routines.

Early warning signs — relapse prevention

Patients and families should develop a personalized relapse prevention plan that identifies:

Lifestyle factors

Sleep regularity is the single most modifiable protective factor for bipolar disorder. Research consistently demonstrates that irregular sleep schedules — regardless of total sleep duration — destabilize circadian rhythms and precipitate mood episodes. Teach:

• Go to bed and wake at the same time every day, including weekends
• Avoid shift work if possible; if unavoidable, use chronotherapy strategies
• Limit caffeine after midday
• Create a consistent wind-down routine
• Track sleep in a mood journal or app

Other lifestyle factors:

• Substance avoidance — alcohol and stimulants (including cannabis in high-THC formulations) reliably destabilize mood and impair medication efficacy
• Regular aerobic exercise — demonstrated mood-stabilizing effects; 30 minutes 3–5 days per week
• Stress management — CBT and interpersonal and social rhythm therapy (IPSRT) are evidence-based psychotherapy approaches for bipolar disorder

Mood charting

Encourage patients to use a daily mood chart or app (e.g., eMoods, Bearable) to track:

• Mood rating (0–10 scale)
• Sleep hours
• Anxiety level
• Medications taken
• Significant events or stressors

Mood charts help patients and providers identify patterns, early warning signs, and triggers — and build the patient’s sense of agency over the illness.

Support resources

• NAMI (National Alliance on Mental Illness): nami.org — education, peer support, helpline
• DBSA (Depression and Bipolar Support Alliance): dbsalliance.org — peer-led support groups, online communities, wellness tools

Discharge planning

Discharge from an inpatient psychiatric unit is a high-risk transition period for patients with bipolar disorder. Relapse and suicide risk are elevated in the weeks following discharge. Comprehensive discharge planning begins on admission.

Outpatient follow-up

• Outpatient psychiatry appointment within 7 days of discharge (evidence base supports this as reducing readmission and suicide risk)
• Psychotherapy referral — CBT, IPSRT, or dialectical behavior therapy (DBT) for comorbid emotional dysregulation
• Primary care follow-up for metabolic monitoring and medication management coordination

Medication management at discharge

• Prescriptions in hand before discharge — do not rely on the patient to arrange pharmacy coordination
• Verify insurance coverage and cost — cost is a major barrier to adherence; document medication assistance programs if needed
• Medication education reviewed and documented
• Confirm patient can articulate what to take, when, and what to do if a dose is missed

Safety planning

Use the Stanley-Brown Safety Planning Intervention (not a “no-harm contract”):

1. Warning signs that a crisis may be developing
2. Internal coping strategies — what the patient can do alone
3. Social contacts and settings that provide distraction
4. People to ask for help
5. Professionals and agencies to contact in a crisis (with phone numbers)
6. Making the environment safer — means restriction

The safety plan should be written, given to the patient, and documented in the chart. Means restriction counseling (particularly regarding firearms and medications) should be conducted with the patient and family.

Social determinants of health

Assess before discharge:

• Housing: Homelessness or unstable housing is a significant relapse risk factor
• Employment: Disability accommodation planning if returning to work
• Insurance and benefits: Ensure continuity of prescription coverage
• Family support: Identify primary support contacts; provide psychoeducation to family
• Transportation: To outpatient appointments

NCLEX-focused high-yield points

1. Lithium toxicity priority action: The first nursing action when lithium toxicity is suspected is to hold the dose and notify the provider — not to administer fluids or check vitals first (hold and notify is the priority intervention, with IV fluids and level drawn as follow-up orders).

2. Lithium and sodium/fluid teaching: Patients on lithium must maintain a consistent sodium intake and drink 2–3 liters of fluid daily. A low-sodium diet causes the kidneys to reabsorb lithium instead of sodium, raising serum levels and causing toxicity. NSAIDs are contraindicated — they reduce renal clearance.

3. Manic patient environment: Priority interventions are reducing stimulation (quiet room, low lighting, minimal visitors) and ensuring safety (remove hazardous items). These are implemented before medication administration in priority-ranking questions.

4. Suicide risk in bipolar vs. unipolar depression: Individuals with bipolar disorder have 20–30 times higher suicide risk than the general population — higher than unipolar depression. Mixed features carry the highest acute risk. On NCLEX, always prioritize safety and suicide assessment for patients with bipolar disorder.

5. Lamotrigine rash: Any rash in a patient taking lamotrigine must be treated as a potential Stevens-Johnson Syndrome (SJS) medical emergency. The correct action is to hold the drug and notify the provider immediately. Do not reassure the patient that it is benign — that determination requires a provider evaluation.

6. Valproate and pregnancy: Valproate is teratogenic — associated with neural tube defects, cardiac defects, and cognitive impairment. It is contraindicated in pregnancy. Women of childbearing potential require REMS enrollment and counseling about contraception before initiation.

7. First indicator of manic relapse: Decreased sleep need (not just duration — the patient feels rested on minimal sleep) is characteristically the earliest warning sign of an emerging manic episode, often appearing before mood or behavioral changes become apparent.

8. DIGFAST mnemonic: Distractibility, Irresponsibility/risky behavior, Grandiosity, Flight of ideas, Activity increase, Sleep decrease, Talkativeness — the seven core features of a manic episode per DSM-5.

9. Therapeutic effect timeline: Mood stabilizers (lithium, valproate) typically require 1–2 weeks for initial effect in acute mania and 2–4 weeks for full effect. Patients and families must understand this timeline to prevent premature discontinuation. Lamotrigine requires 6–8 weeks for antidepressant effect due to slow titration requirements.

10. ECT in bipolar disorder: Electroconvulsive therapy (ECT) is a safe and effective treatment for severe, treatment-resistant bipolar depression and for mixed episodes with severe suicidality or catatonia. It is also used in severe manic episodes that are refractory to pharmacotherapy. On NCLEX, ECT is a priority intervention when medications have failed and the patient is at imminent risk.

Quick reference: common comorbidities in bipolar disorder

Comorbid conditions in bipolar disorder are the rule, not the exception. The most clinically relevant comorbidities and their nursing implications:

For detailed coverage of depression phases, nursing diagnosis, and antidepressant pharmacology, see the depression nursing reference. For antipsychotic pharmacology including EPS and NMS, see the schizophrenia nursing reference. Drug classification context is covered in the drug classifications reference.